Health and Fitness Health and Fitness
Thu, November 15, 2012
Wed, November 14, 2012
Tue, November 13, 2012
Mon, November 12, 2012
Sun, November 11, 2012
Sat, November 10, 2012
Fri, November 9, 2012
Thu, November 8, 2012
Wed, November 7, 2012
Tue, November 6, 2012
Mon, November 5, 2012
Sat, November 3, 2012
Fri, November 2, 2012
Thu, November 1, 2012
Wed, October 31, 2012

ViroPharma To Participate In Two November Healthcare Investor Conferences


//health-fitness.news-articles.net/content/2012/ .. wo-november-healthcare-investor-conferences.html
Published in Health and Fitness on Thursday, November 8th 2012 at 11:16 GMT by Market Wire   Print publication without navigation


ViroPharma To Participate In Two November Healthcare Investor Conferences -- EXTON, Pa., Nov. 8, 2012 /PRNewswire/ --

EXTON, Pa., Nov. 8, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: [ VPHM ]) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 2012 Jefferies Global Healthcare Conference at 11:20 AM GMT (6:20 AM ET) on Thursday, November 15, 2012.  The conference is being held at the Waldorf Hilton in London.

ViroPharma also announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Piper Jaffray 24th Annual Healthcare Conference at 2:00 PM ET on Wednesday, November 28, 2012.  The conference is being held at the New York Palace Hotel.

ViroPharma's presentations will be webcast live for investors through [ www.viropharma.com ] and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at [ http://www.viropharma.com/Products.aspx ]; the prescribing information for other countries can be found at [ www.viropharma.com ]. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, [ www.viropharma.com ]. The company encourages investors to consult these sections for more information on ViroPharma and our business.

 

SOURCE ViroPharma Incorporated



RELATED LINKS
[ http://www.viropharma.com ]

Publication Contributing Sources